July 29, 2019 / 10:57 AM / 23 days ago

Mylan to combine with Pfizer's off-patent medicines unit

July 29 (Reuters) - Mylan NV said on Monday it would combine with Pfizer Inc’s off-patent branded and generic established medicines business to form a global generic drugmaker.

Under the terms of the agreement, which is structured as an all-stock deal, each Mylan share would be converted into one share of the new company.

Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%, Mylan said.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below